FDC
|
|
BOM : 531599     NSE : FDC     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
May 29,2023 |
Price(EOD): βΉ 294.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 4,891.56 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
FDC | 1.6% | 2.7% | 17.9% |
SUN PHARMACEUTICAL INDUSTRIES | 4% | -1.1% | 6.6% |
DIVIS LABORATORIES | 2.8% | 7.5% | -4.1% |
CIPLA | 2.7% | 4.6% | -2% |
DR REDDYS LABORATORIES | 2.2% | -7.4% | 4.1% |
TORRENT PHARMACEUTICALS | 0.8% | 4.6% | 31.3% |
ABBOTT INDIA | 1.8% | -1.2% | 20.3% |
ZYDUS LIFESCIENCES | 1% | -0.6% | 37.9% |
ALKEM LABORATORIES | 2.9% | -2.4% | 14.1% |
FUNDAMENTAL ANALYSIS OF FDC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF FDC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
25.24
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 193.83 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 2.47
P/B Calculated based on Book Value of Rs 1,982.05 Cr
[Latest Year - Mar2023 - Consolidated Results ] 2.74
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,783.75 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
68% -3% -3% |
SHARE PRICE MOMENTUM OF FDC
FDC vs SENSEX
DEBT OF FDC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0 0 0 - |
0 0 0 - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF FDC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF FDC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
6.23% -0.57% -20.29% -24.68% |
27.49% 154.88% 137.79% 195% |
QtrlyTrend |
2 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
FDC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.2% | 3.8% | 3.8% |
S&P BSE MIDSMALLCAP | 1.7% | 6.9% | 17.6% |
S&P BSE 500 | 1.7% | 5.2% | 13.8% |
S&P BSE ALLCAP | 1.7% | 5.3% | 13.9% |
S&P BSE 400 MIDSMALLCAP | 1.7% | 6.4% | 17.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 1.9% | 6.5% | 18.5% |
NIFTY 500 | 1.7% | 5.2% | 14% |
NIFTY500 MULTICAP 50:25:25 | 1.7% | 5.6% | 15.1% |
NIFTY SMALLCAP250 | 1.2% | 6.2% | 14.4% |
You may also like the below Video Courses
FAQ about FDC
Is FDC good for long term investment?
As on May 29,2023, the Fundamentals of FDC look Strong and hence it may be good for long term investment! See Financial Performance of FDC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is FDC UnderValued or OverValued?
As on May 29,2023, FDC is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of FDC ?
As on May 29,2023, the Intrinsic Value of FDC is Rs. 302.46 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 175.50
Fair Value [Median EV / Sales Model] : Rs. 302.46
Fair Value [Median Price / Sales Model] : Rs. 303.13
Estimated Median Fair Value of FDC : Rs. 302.46
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is FDC trading at a Premium or Discount?
As on May 29,2023, FDC is trading at a Discount of -3% based on the estimates of Median Intrinsic Value!